Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxy-3-methylglutaryl coenzyme a (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro
- 9 February 1999
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 57 (6) , 697-703
- https://doi.org/10.1016/s0006-2952(98)00341-4
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDLAtherosclerosis, 1997
- FluvastatinDrugs, 1996
- The resistance of low density lipoprotein to oxidation promoted by copper and its use as an index of antioxidant therapyAtherosclerosis, 1996
- Antioxidant properties of demethyldiisoeugenolBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1995
- Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions.Journal of Clinical Investigation, 1994
- Peroxynitrite modification of low‐density lipoprotein leads to recognition by the macrophage scavenger receptorFEBS Letters, 1993
- Pharmacokinetics of Fluvastatin After Single and Multiple Doses in Normal VolunteersThe Journal of Clinical Pharmacology, 1992
- Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man.Journal of Clinical Investigation, 1989
- Potentiation of atherosclerotic lesions in rabbits by a high dietary level of vitamin EBritish Journal of Nutrition, 1989
- THE DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUMJournal of Clinical Investigation, 1955